Recovery & Tissue Repair · Reviewed by Ian K. Tseng, MD

What Is TB-500? Thymosin Beta-4 and Its Restricted Status

TB-500 is usually mentioned in the same breath as BPC-157, and the two share more than a reputation — they share a regulatory status that puts both outside the reach of any legitimate compounding pharmacy in the United States. Here is what the compound is, what the research examines, and why you should be skeptical of anyone offering it.

Published August 4, 2026 · Medical review by Ian K. Tseng, MD, Medical Director

Plain unlabeled laboratory vial on a bare clinical surface, representing a compound Soothe IV does not offer

Not offered by Soothe IV

This compound cannot be legally prepared by a compounding pharmacy under current FDA restrictions. We do not prescribe or dispense it. This article is here because the question deserves a straight answer, not because we are selling anything.

The short answer

TB-500 is a synthetic peptide corresponding to a short active region of thymosin beta-4, a naturally occurring protein involved in actin regulation and cell migration. Research has examined effects on angiogenesis, cell motility, and tissue repair, predominantly in preclinical models. It appears on the World Anti-Doping Agency prohibited list, and FDA restrictions on the relevant bulk substance place it outside legitimate compounding. Soothe IV does not offer it.

Thymosin beta-4 and the fragment

Thymosin beta-4 is a naturally occurring protein of 43 amino acids found broadly in human tissue and in wound fluid. Its best-characterized biological role is binding actin — the protein that forms much of the cell's internal scaffolding — and regulating its assembly. Because actin dynamics underlie cell movement, thymosin beta-4 is involved in processes where cells need to migrate, including wound repair.

TB-500 is not thymosin beta-4 itself. It is a synthetic peptide corresponding to a short region of the parent molecule containing the actin-binding site. The distinction matters because research conducted on full thymosin beta-4 is often cited as though it establishes the properties of the fragment, which is not a sound inference.

What the research examines

Preclinical work has examined thymosin beta-4 and related fragments for effects on angiogenesis, cell migration, inflammation modulation, and tissue repair in models including cardiac, corneal, and dermal injury. Some of this research is genuinely interesting and has been pursued in clinical development programs for specific indications.

That said, the body of evidence supporting the uses TB-500 is marketed for online — athletic recovery, soft-tissue injury healing in otherwise healthy adults — is thin, and largely does not consist of controlled human trials in that population. As with any compound in this space, preclinical promise and demonstrated human benefit are different categories of claim.

Two separate restrictions

TB-500 carries two distinct restrictions that are often conflated.

The first is anti-doping. TB-500 appears on the World Anti-Doping Agency Prohibited List. Any athlete subject to WADA-code testing — competitive, collegiate, professional, or Olympic-pathway — risks a sanction from use, regardless of how it was obtained. This is a live consideration for a meaningful segment of the people who search for it.

The second is pharmaceutical. FDA restrictions on the relevant bulk substance under the 503A compounding framework place it outside what a compounding pharmacy can legally prepare, on the same basis that applies to BPC-157 — insufficient safety characterization for compounding use. There is no compliant route to a legitimate prescription.

What is actually being sold

TB-500 is readily available online under the "research use only" or "not for human consumption" label. That label is the legal mechanism enabling sale outside the prescription framework — no prescription, no physician evaluation, no purity standard verified for human administration, no dosing guidance from human data, and no accountability.

For an athlete, add the anti-doping exposure on top. For anyone, the underlying problem is the same one we describe in are peptides safe?: a Certificate of Analysis tells you what is in the vial and nothing about whether it belongs in you.

If recovery is the goal

The compounds with the loudest online reputations in the recovery category are, at present, the ones a legitimate program cannot provide. That is an unsatisfying answer, and it is the accurate one.

What a physician can evaluate is whether any therapy within the available prescription framework is appropriate for your situation — and sometimes the clinically correct answer is that the issue is better addressed outside of peptide therapy entirely. That determination comes after evaluation and bloodwork, not before.

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a naturally occurring 43-amino-acid protein involved in actin regulation and cell migration. TB-500 is a synthetic peptide corresponding to a short region of that parent molecule containing the actin-binding site. Research conducted on full thymosin beta-4 is frequently cited as though it establishes the properties of the fragment, which is not a sound inference.

Is TB-500 banned in sports?

Yes. TB-500 appears on the World Anti-Doping Agency Prohibited List. Any athlete subject to WADA-code testing — competitive, collegiate, professional, or Olympic-pathway — risks sanction from its use regardless of how it was obtained.

Why does Soothe IV not offer TB-500?

FDA restrictions on the relevant bulk substance under the 503A compounding framework place it outside what a licensed compounding pharmacy can legally prepare, on the same basis that applies to BPC-157. There is no compliant route to a legitimate prescription. Our program requires a licensed physician, a Good Faith Examination, bloodwork, and a licensed 503A pharmacy.

What does the TB-500 research show?

Preclinical work on thymosin beta-4 and related fragments has examined angiogenesis, cell migration, inflammation modulation, and tissue repair in cardiac, corneal, and dermal injury models. Evidence supporting the uses TB-500 is marketed for online — athletic recovery and soft-tissue healing in otherwise healthy adults — is thin and largely does not consist of controlled human trials in that population.

Clinical references

Medically reviewed by Ian K. Tseng, MD, Medical Director of Soothe IV's peptide therapy program. The clinical statements in this article are supported by the following sources:

Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy. 2012. pubmed.ncbi.nlm.nih.gov
World Anti-Doping Agency. The Prohibited List. www.wada-ama.org
U.S. Food & Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A. www.fda.gov

Ready to talk to a physician?

Start your $50 Application. A physician reviews your goals and labs and tells you what — if anything — fits your situation, including when the answer is that peptide therapy is not the right approach. Your fee credits in full toward your first month of membership. Available nationwide.

Book & Pay for Your $50 Application

Serving Orange County, Los Angeles, and San Diego — plus nationwide telehealth. All service areas.

This article is educational and is not medical advice. Statements have not been evaluated by the FDA. Peptide therapy is a physician-supervised medical service; specific protocols are determined individually after a Good Faith Examination and bloodwork, and not all applicants qualify. Some compounded medications used in physician-prescribed protocols are not FDA-approved. Data from clinical trials on FDA-approved medications should not be used to make assessments related to compounded medications. Soothe IV's peptide program is available nationwide via telehealth; prescriptions are issued by physicians licensed in your state.